Our lead product-CRMD001-are unique proprietary formulations of the oral iron chelator, Deferiprone. We currently have FDA-approved Investigational New Drug (IND) applications for the use of CRMD001 for the prevention of contrast-induced AKI (Phase II, with approved Phase III SPA) and for treatment of CKD (Phase II). Deferiprone, the first oral iron chelator, is approved for use in more than 50 countries (ex -U.S.) for the treatment of iron overload.
There is considerable experimental and human data supporting the role of labile iron in the pathogenesis of AKI and also progression of CKD. Deferiprone appears to possess unique characteristics as an iron binding compound that makes it particularly attractive for these important indications.
We have worldwide rights to develop, manufacture and market CRMD001.